(Q30332444)

18 June 2017

1 reference

title

Novel agents and strategies to treat herpes simplex virus infections. (English)

1 reference

18 June 2017

Gerald Kleymann

1

1 reference

PubMed ID

12556212

18 June 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Investigational Drugs

18 June 2017

1 reference

18 June 2017

12

1 reference

18 June 2017

2

1 reference

18 June 2017

165-183

1 reference

Diagnosis of herpes simplex virus infections

18 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Prospects for control of herpes simplex virus disease through immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Herpes simplex viruses: is a vaccine tenable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Therapeutic vaccination against chronic viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Vaccines against genital herpes: progress and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Live-attenuated varicella vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Immunological hiding of herpesvirus-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Herpes simplex virus evolved to use the human defense mechanisms to establish a lifelong infection in neurons--a review and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Imiquimod and resiquimod as novel immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Resistance to ocular herpes simplex virus type 1 infection in IL-12 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

THERAPEUTIC ANTIVIRAL ACTION OF 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE IN HERPES SIMPLEX KERATITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Anti-herpes viruses agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Antiviral therapy of herpes simplex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

New treatments for genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Non-nucleoside inhibitors of herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

The management of herpes simplex virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

New developments in the epidemiology, natural history and management of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Antiviral agents for non-human immunodeficiency virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

The evolution of antiviral therapy for external ocular viral infections over twenty-five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Treatment of viral diseases of the cornea and external eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Herpes simplex virus antiviral drug resistance--current trends and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Mechanisms of herpes virus resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Acyclovir-resistant, pathogenic herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

The herpesvirus proteases as targets for antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Inhibition of herpes proteases and antiviral activity of 2-substituted thieno[2,3-d]oxazinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type 1 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: a new class of antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Selective inhibition of herpes simplex virus ribonucleoside diphosphate reductase by derivatives of 2-acetylpyridine thiosemicarbazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Herpes simplex virus type 1 uracil-DNA glycosylase: isolation and selective inhibition by novel uracil derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

The structural basis of specific base-excision repair by uracil-DNA glycosylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Molecular modeling and synthesis of inhibitors of herpes simplex virus type 1 uracil-DNA glycosylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Nucleoside analogues as highly potent and selective inhibitors of herpes simplex virus thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Prediction of the binding mode of N2-phenylguanine derivative inhibitors to herpes simplex virus type 1 thymidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Synthesis, properties, and pharmacokinetic studies of N2-phenylguanine derivatives as inhibitors of herpes simplex virus thymidine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

New anti-HSV therapeutics target the helicase-primase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Effect of Novobiocin and Other DNA Gyrase Inhibitors on Virus Replication and DNA Synthesis in Herpes Simplex Virus Type 1-infected BHK Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Cyclic variations of 3-quinolinecarboxamides and effects on antiherpetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Role of DNA topoisomerase I in the replication of herpes simplex virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.165

10.1517/13543784.12.2.165

21 January 2018

Identifiers

DOI

1 reference

18 June 2017

1 reference

PubMed ID

12556212